The Carlyle Group, a global investment firm has announced an agreement to invest in Tokiwa Corporation, known for research, development and manufacturing of cosmetic products, through a strategic business and capital alliance.
 
Headquartered in Nakatsugawa, Gifu, Tokiwa has been established for more than 70 years and is well-known for its innovations in cosmetic formulations and componentry. The company has advanced research and development capabilities with more than 400 patents worldwide, and is a supplier to prominent beauty brands around the world. A steady supply of high-quality products and its agility to respond to rapidly growing market demand has enabled Tokiwa to develop a strong reputation among its business partners. The company is also well positioned to benefit from the rising demand and admiration for safe, quality “Made in Japan” cosmetic products, fueled by a booming tourism market.
 
Through the alliance, Tokiwa will work with Carlyle to establish itself as a global leader in the cosmetics manufacturing industry. Carlyle will leverage its in-depth knowledge of the cosmetics and consumer industries, corporate management skills, as well as its global network, to support Tokiwa’s marketing efforts and brand positioning in the growing global cosmetics market and lay the foundations for the company’s business expansion. Carlyle will help Tokiwa and its partners achieve further growth, deliver value to consumers, and support Tokiwa to become a “valuable global company that can continue sustained, long-term growth” as indicated in the company‘s philosophy.
 
Hitomi Hibino, executive vice president of Tokiwa, said, “Since our founding, we have continued to change and innovate. With ‘Sustainable Innovation’ as our motto, we have always strived to turn our customers’ confidence into lasting trust. We are pleased to work with Carlyle, which has a proven record in Japan and will add impetus to our organization’s initiatives.”
 
Tokiwa New Jersey
Tokiwa is opening a new $30-million facility in Monroe Township, NJ. It encompasses a 153,000-plus sq. ft. standalone building, located on 12-plus acres. The FDA registered facility will be capable of producing OTC and SPF rated products and will operate under cGMP certification.
 
Robert Congionti, VP of operations, stated: “Our company’s objective is to deliver Japanese quality and standards at competitive prices for all our customers.”